

EDITED BY C. GLEN MAYHALL, MD
MURRAY D. BATT, MD
EDWARD S. WONG, MD

SHEA News

THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA

PRESIDENT	Peter A. Gross, MD/Hackensack, New Jersey	TREASURER	Elias Abrutyn, MD/Philadelphia, Pennsylvania
PRESIDENT-ELECT	Bryan F. Simmons, MD/Memphis, Tennessee	COUNCILOR	Michael D. Decker, MD/Nashville, Tennessee
VICE PRESIDENT	William J. Martone, MD/Atlanta, Georgia	COUNCILOR	Leigh G. Donowitz, MD/Charlottesville, Virginia
PAST PRESIDENT	Donald E. Craven, MD/Boston, Massachusetts	COUNCILOR	Timothy W. Lane, MD/Greensboro, N. Carolina
SECRETARY	Dale N. Gerding, MD/Chicago, Illinois	COUNCILOR	H. Gunner Deery, II, MD/Petoskey, Michigan

Natural Rubber Latex Reactions Follow Up Needed

As data is gathered on the definition and prevalence of allergy to natural rubber latex, some hospitals are trying to determine whether there is a current rational approach to the issue of whether patients who require alternative products in their care can be identified prospectively. Some of the questions that need to be addressed are: 1) What screening tool

do you believe is appropriate to identify patients who have had or who are at risk for systemic reactions to latex? 2) Are you using such a tool in day-to-day operations at your healthcare facilities (hospitals, surgicenters, etc.) 3) How do you manage a patient who is at risk of a systemic reaction to natural rubber latex? 4) How frequently have you felt

it appropriate to use an identification of being "at risk of systemic reaction to latex" in the day-to-day operations of your facility? Please FAX ([708] 3182332) or mail your response to these questions to Murray D. Batt, MD, Hospital Epidemiology, LGHS, 1775 Dempster, Park Ridge, IL 60068, and they will be summarized and shared in a future news page.

Health Employer Data and Information Set (HEDIS 2.0)

Employers such as Xerox currently encourage their employees to join HMOs. Xerox already has reached about 80% HMO membership for its employees. Xerox, among other large employers, requires that the health plans in which it pays for employee participation make available report card information that is specified in the HEDIS 2.0 criteria, published by the National Committee for Quality Assurance in July 1993.

HEDIS 2.0 addresses 70 questions in five sections: Quality, Access and Satisfaction, Membership and Utilization, Finance, and Descriptive Information. Quality measures address the success achieved by the health plan in

delivering childhood immunizations, cholesterol screening, mammography screening, and PAP smears. They also query rates of low and very low birthweight babies, as well as prenatal care. Additional quality measures for acute and chronic disease required by HEDIS 2.0 are asthma inpatient admission and readmission rates, rates of dilated retinal examination for diabetics in the plan, and rates of

ambulatory follow-up after hospitalization for major affective disorders.

As healthcare organization epidemiologists, we will have more opportunity to help prepare for and evaluate the efforts to obtain data such as that required by HEDIS 2.0 as national momentum builds toward managed care and external reporting of the quality of care delivered in managed care organizations.

Brief items of interest for the SHEA News or Newsletter may be sent to C. Glen Mayhall, MD, SHEA, Newsletter Editor, Division of Infectious Diseases, Route 1092; The Former Shriner's Burns Bldg, Room 2-64B; University of Texas Medical Branch; Galveston, TX 77555-1092; FAX (409) 772-6527. Copy should be typed, double-spaced, and should not exceed five pages.

Classified Marketplace

re . sponse \ri-`spän(t)s\

That's what you want from a classified ad. And Classified Marketplace lets you reach the audience you want-cost effectively-to get you the response you need.

- Employment Opportunities
- Educational Opportunities
- Positions Wanted
- For Sale/For Rent
- Meetings
- Miscellaneous
- Services
- Wanted

RATES

Typesetting available
Line Advertising-\$23 per line,
\$138 minimum

Classified advertising is non-commissionable

Contact our Classified Advertising Representative for help in placing your customized ad message:

Call toll-free 1-800-257-8290 or send typed copy to:


F A X #609-853-5991 INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY



Donna Coles • 6900 Grove Road
Thorofare, NJ 08086-9447


ROOM PRESSURE MONITORING

Room Monitors



Manometers

Switches



Transmitters



Ideal for measuring, controlling, or monitoring very low differential pressures. Applications include tuberculosis isolation rooms, reverse precaution rooms, sputum induction rooms, and aerosol administration areas.

Call or write today.

MODUS

10 Beat-foot Road
Northboro, MA 01532
USA (508) 393-8991
Fax:(508) 393-8099

Tuberculosis Control



If Performance were your only consideration in buying an air treatment system to combat TB, you would choose the NQ 500.

If Price were your only consideration, you would *still* choose the NQ 500.

We invite you to compare our air treatment system with all other major brands. To receive a free comparison chart and complete information on the NQ 500, call our toll-free number:



ONLY ONE GETS YOU INTO ALL THE LEADING NEEDLE-LESS IV SYSTEMS


Only TUBEX® Blunt Pointe™ prefilled cartridge unit is compatible with **InterLink®, LifeShield®, SAFSITE®** and **USER-GARD™**.*

Unlike other cannulas that can limit you to a single needle-less system, TUBEX® Blunt Pointe™ can help maximize your investment by providing the flexibility of multisystem use plus a broad range of prefilled products.

What's more, its precision design can make it even easier to use. In a recent independent study, TUBEX® Blunt Pointe™ took less than half the *effort* to insert into the InterLink® System compared to the InterLink® System Cannula—the only cannula used with the Carproject® needle-less system.

Of course, like all TUBEX® products, TUBEX® Blunt Pointe™ facilitates meeting OSHA and FDA safety standards.³

Open your needle-less IV system to its full potential. Choose TUBEX® Blunt Pointe™ prefilled cartridge unit—the only one that helps your system work harder for you.



Tubex®
(closed injection system)
Blunt Pointe™
Sterile Cartridge Unit

IV SAFETY MADE SIMPLE™

*Consult manufacturer's recommendations regarding "directions for use" for the needle-less system.

†For the SAFSITE® Reflux Valve, aseptically swab the Luer slip fitting of the Blunt Pointe™ sterile cartridge tip assembly with a sterile, individually wrapped, saturated 70% isopropyl alcohol swab. This action will remove the lubricant coating from the tip to facilitate a tight seal.

InterLink® is a registered trademark of Baxter International Inc. LifeShield® is a registered trademark of Abbott Laboratories. SAFSITE® is a registered trademark of B. Braun Medical Inc. USER-GARD™ is a trademark of Arrow International Inc. Carproject® is a registered trademark of Sonofi Winthrop Pharmaceuticals.

References: 1. Data on file, Wyeth-Ayerst Laboratories. 2. Occupational Exposure to Bloodborne Pathogens; Final Rule. 56 Fed. Reg. 64175 (1991) (29 CFR 1910.1030). 3. FDA Safety Alert: Needlestick and Other Risks from Hypodermic Needles on Secondary I.V. Administration Sets — Piggyback and Intermittent I.V. Rockville, Md: Food and Drug Administration; April, 1992.

© 1994, Wyeth-Ayerst Laboratories.
64067

WYETH-AYERST
LABORATORIES
Philadelphia, PA 19101